Yeast-derived Glycoprotein B-1 of Herpes Simplex Virus (HSV) as a Candidate for an HSV Vaccine
Although antiherpes drugs such as acyclovir or Ara-A are available, herpes simplex virus (HSV) infections are still a serious clinical problem. Under the circumstances, as a method of prophylaxis, vaccine development seems to be very important. As candidates for HSV vaccines, deletion-mutant live attenuated vaccines (1) and subunit vaccines consisting of viral glycoproteins (2, 3) have been extensively investigated.
KeywordsElectrophoresis Diethyl Dodecyl Acyclovir Berman
Unable to display preview. Download preview PDF.
- 10.Burke, R. L., Van Nest, G., Carlson, J., Gervase, B., Goldbeck, C., Ng, P., Sanchez-Pescador, L., Stanberry, L. R. and Ott, G. (1989) in Vaccines 89 ( Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. ), pp. 377–382.Google Scholar
- 11.Meignier, B., Jourdier, T. M., Norrild, B., Pereira, L. and Roizman, B. (1987) J. Infect. Dis. 155921–930.Google Scholar